Table 3.
Treatment of brain metastases from colorectal cancer
| Initial treatment period | First half 1997–2005 | Second half 2006–2015 | p value |
|---|---|---|---|
| Treatment of brain metastases | |||
| WBRT or WBRT + SRT | 21 (58%) | 3 (9%) | 0.004 |
| SRT | 4 (11%) | 13 (41%) | |
| Surgery + SRT | 3 (8%) | 4 (13%) | |
| Surgery or Surgery + WBRT | 4 (11%) | 9 (28%) | |
| Supportive care | 4 (11%) | 3 (9%) | |
| Regimen before diagnosis of brain metastases | |||
| None | 13 (36%) | 9 (28%) | 0.011 |
| Fluoropyrimidine only | 9 (25%) | 4 (13%) | |
| Fluoropyrimidine + oxaliplatin | 2 (6%) | 4 (13%) | |
| Fluoropyrimidine + irinotecan | 6 (17%) | 0 (0%) | |
| Fluoropyrimidine + oxaliplatin + irinotecan | 6 (17%) | 15 (46%) | |
| Targeted agents | |||
| Not used | 34 (94%) | 11 (34%) | <.0001 |
| Used | 2 (6%) | 21 (66%) | |
WBRT Whole brain radiotherapy, SRT Stereotactic radiotherapy